Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: Results of the ENTIRE-thrombolysis in myocardial infarction (TIMI) 23 trial

Circulation

Volumn 105, Issue 14, 2002, Pages 1642-1649

  Antman, Elliott M ^a   Louwerenburg, Hans W ^a   Baars, Hubert F ^a   Wesdorp, Jan C L ^a   Hamer, Bas ^a   Bassand, Jean Pierre ^a   Bigonzi, Frederique ^a   Pisapia, Ghislaine ^a   Gibson, C Michael ^a   Heidbuchel, Hein ^a   Braunwald, Eugene ^a   Van de Werf, Frans ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Anticoagulants; Fibrinolysis; Heparin; Myocardial infarction

Indexed keywords

ABCIXIMAB; ENOXAPARIN; HEPARIN; TENECTEPLASE; THROMBIN INHIBITOR;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ELECTROCARDIOGRAPHY; FEMALE; FIBRINOLYSIS; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION;

AGED; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; BLOOD FLOW VELOCITY; COHORT STUDIES; CORONARY ANGIOGRAPHY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; ENOXAPARIN; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HEPARIN; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; RECURRENCE; RISK ASSESSMENT; SURVIVAL RATE; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 0037046221     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000013402.34759.46     Document Type: Article

References (23)

1. Bolus fibrinolytic therapy in acute myocardial infarction
2. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: The ASSENT-2 double-blind randomised trial
3. The search for replacements for unfractionated heparin
4. Early ST-segment elevation resolution: Predictor of outcome and angiographic patency in patients with acute myocardial infarction. Results of the AMI-SK study
5. Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: Second trial of Heparin and Aspirin Reperfusion Therapy (HART II)
6. Thrombolysis in Myocardial Infarction (TIMI) Trial, phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase
7. TIMI frame count: A quantitative method of assessing coronary artery flow
8. Extent of early ST segment elevation resolution: A strong predictor of outcome in patients with acute myocardial infarction and a sensitive measure to compare thrombolytic regimens: A substudy of the International Joint Efficacy Comparison of Thrombolytics (INJECT) trial
9. Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction: Observations from the TIMI 14 trial
10. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial
11. Hirudin in acute myocardial infarction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial
12. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI), phase II trial
13. Abciximab facilitates the rate and extent of thrombolysis: Results of the thrombolysis in myocardial infarction (TIMI) 14 trial
14. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: The ASSENT-3 randomised trial in acute myocardial infarction
15. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: The GUSTO V randomised trial
16. A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction
17. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction
18. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction
19. Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: Results of a randomised double blind European Cooperative Study Group trial
20. Issues regarding the use of heparin following streptokinase therapy
21. Heparin as an adjunctive treatment after thrombolytic therapy for acute myocardial infarction
22. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris
23. Pharmacokinetic study of enoxaparin in patients undergoing coronary intervention after treatment with subcutaneous enoxaparin in acute coronary syndromes: The PEPCI study